Creative Planning
MLNT

Creative Planning’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Creative Planning’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,200
Closed -$40K – 2166
2019
Q1 		$40K Buy
11,200
+7,754
+225% +$42.1K ﹤0.01% 1797
2018
Q4 		$14K Buy
3,446
+668
+24% +$8.54K ﹤0.01% 1814
2018
Q3 		$55K Buy
2,778
+100
+4% +$2.53K ﹤0.01% 1868
2018
Q2 		$85K Buy
2,678
+20
+0.8% +$720 ﹤0.01% 1795
2018
Q1 		$98K Buy
+2,658
New +$175K ﹤0.01% 1755

Other funds holding MLNT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

Creative Planning's MLNT Position: Q2 2019 in Review

Creative Planning sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q2 2019, closing a stake of 11,200 shares — an estimated $40K sold.

Creative Planning first reported a position in MLNT in Q1 2018 and held it in 5 quarters. The position peaked at $98K in Q1 2018. 53 funds tracked by Wall St. Rank hold MLNT as of Q2 2019.

  • Creative Planning reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Creative Planning sold 11,200 Melinta Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $40K.
  • Creative Planning first reported a position in Melinta Therapeutics, Inc. Common Stock in Q1 2018 and held it in 5 quarters.
  • Creative Planning's Melinta Therapeutics, Inc. Common Stock position peaked at $98K in Q1 2018.
  • 53 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Creative Planning's 13F filing for Q2 2019, filed 26 Jul 2019.